Interpace Biosciences, Inc. Logo

Interpace Biosciences, Inc.

IDXG

(2.2)
Stock Price

3,40 USD

21.63% ROA

-10.7% ROE

3.13x PER

Market Cap.

8.831.624,00 USD

-67.17% DER

0% Yield

6.73% NPM

Interpace Biosciences, Inc. Stock Analysis

Interpace Biosciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Interpace Biosciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-0.08x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (-24%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Net Profit Growth

Throughout the past five years, this company has consistently experienced net profit growth, indicating a strong financial performance and making it an attractive investment prospect.

4 ROE

The stock's ROE falls within an average range (3.42%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

6 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

7 ROA

The stock's ROA (-13.58%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-11), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Interpace Biosciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Interpace Biosciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Interpace Biosciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Interpace Biosciences, Inc. Revenue
Year Revenue Growth
1997 54.700.000
1998 101.100.000 45.9%
1999 174.900.000 42.2%
2000 416.875.000 58.04%
2001 696.583.000 40.15%
2002 284.013.000 -145.26%
2003 317.448.000 10.53%
2004 364.444.000 12.9%
2005 319.415.000 -14.1%
2006 239.242.000 -33.51%
2007 117.131.000 -104.25%
2008 112.528.000 -4.09%
2009 84.871.000 -32.59%
2010 144.652.000 41.33%
2011 157.291.000 8.04%
2012 126.899.000 -23.95%
2013 150.842.000 15.87%
2014 119.935.000 -25.77%
2015 9.432.000 -1171.58%
2016 13.085.000 27.92%
2017 15.897.000 17.69%
2018 21.896.000 27.4%
2019 24.079.000 9.07%
2020 32.398.000 25.68%
2021 41.314.000 21.58%
2022 31.838.000 -29.76%
2023 36.312.000 12.32%
2023 40.214.000 9.7%
2024 48.168.000 16.51%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Interpace Biosciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 255.000 100%
2015 2.292.000 88.87%
2016 1.647.000 -39.16%
2017 1.461.000 -12.73%
2018 2.124.000 31.21%
2019 2.810.000 24.41%
2020 2.795.000 -0.54%
2021 1.882.000 -48.51%
2022 703.000 -167.71%
2023 596.000 -17.95%
2023 636.000 6.29%
2024 584.000 -8.9%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Interpace Biosciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 48.739.000 100%
2010 36.509.000 -33.5%
2011 34.284.000 -6.49%
2012 27.869.000 -23.02%
2013 28.687.000 2.85%
2014 29.152.000 1.6%
2015 16.922.000 -72.27%
2016 10.504.000 -61.1%
2017 9.153.000 -14.76%
2018 8.499.000 -7.7%
2019 14.546.000 41.57%
2020 20.770.000 29.97%
2021 13.669.000 -51.95%
2022 10.973.000 -24.57%
2023 8.496.000 -29.15%
2023 9.363.000 9.26%
2024 8.564.000 -9.33%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Interpace Biosciences, Inc. EBITDA
Year EBITDA Growth
1997 9.000.000
1998 7.500.000 -20%
1999 14.600.000 48.63%
2000 38.089.000 61.67%
2001 15.424.000 -146.95%
2002 -37.895.000 140.7%
2003 27.700.000 236.81%
2004 40.328.000 31.31%
2005 -25.511.000 258.08%
2006 13.448.000 289.7%
2007 -7.610.000 276.71%
2008 -29.007.000 73.76%
2009 -4.524.000 -541.18%
2010 -2.467.000 -83.38%
2011 -1.642.000 -50.24%
2012 25.248.000 106.5%
2013 -2.852.000 985.27%
2014 -9.061.000 68.52%
2015 -25.925.000 65.05%
2016 -11.155.000 -132.41%
2017 -10.770.000 -3.57%
2018 -7.082.000 -52.08%
2019 -20.085.000 64.74%
2020 -21.627.000 7.13%
2021 -8.182.000 -164.32%
2022 -3.781.000 -116.4%
2023 -64.000 -5807.81%
2023 3.837.000 101.67%
2024 9.780.000 60.77%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Interpace Biosciences, Inc. Gross Profit
Year Gross Profit Growth
1997 10.400.000
1998 23.400.000 55.56%
1999 46.000.000 49.13%
2000 114.600.000 59.86%
2001 135.783.000 15.6%
2002 29.873.000 -354.53%
2003 89.081.000 66.47%
2004 98.830.000 9.86%
2005 61.936.000 -59.57%
2006 55.844.000 -10.91%
2007 31.615.000 -76.64%
2008 4.513.000 -600.53%
2009 26.280.000 82.83%
2010 32.204.000 18.4%
2011 32.471.000 0.82%
2012 26.860.000 -20.89%
2013 24.410.000 -10.04%
2014 18.541.000 -31.65%
2015 2.522.000 -635.17%
2016 6.444.000 60.86%
2017 8.539.000 24.53%
2018 11.699.000 27.01%
2019 8.191.000 -42.83%
2020 10.725.000 23.63%
2021 17.945.000 40.23%
2022 18.231.000 1.57%
2023 19.816.000 8%
2023 23.043.000 14%
2024 29.724.000 22.48%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Interpace Biosciences, Inc. Net Profit
Year Net Profit Growth
1997 -4.200.000
1998 9.500.000 144.21%
1999 10.400.000 8.65%
2000 27.028.000 61.52%
2001 6.354.000 -325.37%
2002 -30.761.000 120.66%
2003 12.258.000 350.95%
2004 21.132.000 41.99%
2005 -19.454.000 208.63%
2006 11.809.000 264.74%
2007 -9.974.000 218.4%
2008 -34.461.000 71.06%
2009 -33.560.000 -2.68%
2010 -6.814.000 -392.52%
2011 -11.914.000 42.81%
2012 -25.527.000 53.33%
2013 -4.565.000 -459.19%
2014 -16.073.000 71.6%
2015 -11.356.000 -41.54%
2016 -8.332.000 -36.29%
2017 -12.216.000 31.79%
2018 -12.189.000 -0.22%
2019 -26.639.000 54.24%
2020 -26.201.000 -1.67%
2021 -14.746.000 -77.68%
2022 -5.865.000 -151.42%
2023 -2.456.000 -138.8%
2023 802.000 406.23%
2024 8.248.000 90.28%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Interpace Biosciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 -5
1998 9 144.44%
1999 9 -12.5%
2000 20 60%
2001 5 -400%
2002 -22 119.05%
2003 8 362.5%
2004 14 42.86%
2005 -14 207.69%
2006 9 262.5%
2007 -7 214.29%
2008 -24 70.83%
2009 -24 -4.35%
2010 -5 -475%
2011 -8 50%
2012 -18 52.94%
2013 -3 -466.67%
2014 -108 97.2%
2015 -73 -46.58%
2016 -46 -62.22%
2017 -8 -542.86%
2018 -4 -75%
2019 -7 42.86%
2020 -7 -16.67%
2021 -4 -100%
2022 -1 -200%
2023 -1 0%
2023 0 0%
2024 2 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Interpace Biosciences, Inc. Free Cashflow
Year Free Cashflow Growth
1997 3.100.000
1998 12.400.000 75%
1999 4.200.000 -195.24%
2000 11.242.000 62.64%
2001 64.566.000 82.59%
2002 -92.992.000 169.43%
2003 39.802.000 333.64%
2004 20.878.000 -90.64%
2005 -2.717.000 868.42%
2006 17.915.000 115.17%
2007 -7.185.000 349.34%
2008 -16.390.000 56.16%
2009 -17.702.000 7.41%
2010 14.222.000 224.47%
2011 1.642.000 -766.14%
2012 -11.398.000 114.41%
2013 -5.330.000 -113.85%
2014 -27.729.000 80.78%
2015 -20.195.000 -37.31%
2016 -8.940.000 -125.89%
2017 -15.292.000 41.54%
2018 -9.122.000 -67.64%
2019 -19.088.000 52.21%
2020 -16.154.000 -18.16%
2021 -9.073.000 -78.04%
2022 -8.014.000 -13.21%
2023 3.319.000 341.46%
2023 393.000 -744.53%
2024 1.207.000 67.44%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Interpace Biosciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
1997 3.400.000
1998 14.400.000 76.39%
1999 5.600.000 -157.14%
2000 19.107.000 70.69%
2001 80.126.000 76.15%
2002 -88.980.000 190.05%
2003 41.631.000 313.73%
2004 28.982.000 -43.64%
2005 3.115.000 -830.4%
2006 19.685.000 84.18%
2007 -6.176.000 418.73%
2008 -15.991.000 61.38%
2009 -15.972.000 -0.12%
2010 16.352.000 197.68%
2011 1.985.000 -723.78%
2012 -10.286.000 119.3%
2013 -3.512.000 -192.88%
2014 -16.378.000 78.56%
2015 -19.842.000 17.46%
2016 -8.940.000 -121.95%
2017 -15.263.000 41.43%
2018 -8.673.000 -75.98%
2019 -18.957.000 54.25%
2020 -14.579.000 -30.03%
2021 -8.719.000 -67.21%
2022 -7.692.000 -13.35%
2023 3.789.000 303.01%
2023 393.000 -864.12%
2024 1.404.000 72.01%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Interpace Biosciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
1997 300.000
1998 2.000.000 85%
1999 1.400.000 -42.86%
2000 7.865.000 82.2%
2001 15.560.000 49.45%
2002 4.012.000 -287.84%
2003 1.829.000 -119.35%
2004 8.104.000 77.43%
2005 5.832.000 -38.96%
2006 1.770.000 -229.49%
2007 1.009.000 -75.42%
2008 399.000 -152.88%
2009 1.730.000 76.94%
2010 2.130.000 18.78%
2011 343.000 -520.99%
2012 1.112.000 69.15%
2013 1.818.000 38.83%
2014 11.351.000 83.98%
2015 353.000 -3115.58%
2016 0 0%
2017 29.000 100%
2018 449.000 93.54%
2019 131.000 -242.75%
2020 1.575.000 91.68%
2021 354.000 -344.92%
2022 322.000 -9.94%
2023 470.000 31.49%
2023 0 0%
2024 197.000 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Interpace Biosciences, Inc. Equity
Year Equity Growth
1997 -1.100.000
1998 47.600.000 102.31%
1999 60.800.000 21.71%
2000 138.110.000 55.98%
2001 150.935.000 8.5%
2002 123.211.000 -22.5%
2003 138.488.000 11.03%
2004 165.425.000 16.28%
2005 135.610.000 -21.99%
2006 149.197.000 9.11%
2007 140.189.000 -6.43%
2008 107.107.000 -30.89%
2009 74.890.000 -43.02%
2010 69.513.000 -7.74%
2011 59.523.000 -16.78%
2012 35.630.000 -67.06%
2013 32.479.000 -9.7%
2014 20.122.000 -61.41%
2015 13.038.000 -54.33%
2016 6.531.000 -99.63%
2017 39.969.000 83.66%
2018 32.938.000 -21.35%
2019 13.026.000 -152.86%
2020 -29.083.000 144.79%
2021 -42.418.000 31.44%
2022 -63.072.000 32.75%
2023 -16.144.000 -290.68%
2023 -15.136.000 -6.66%
2024 -12.490.000 -21.18%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Interpace Biosciences, Inc. Assets
Year Assets Growth
1997 12.400.000
1998 69.900.000 82.26%
1999 103.000.000 32.14%
2000 270.225.000 61.88%
2001 302.671.000 10.72%
2002 190.939.000 -58.52%
2003 219.623.000 13.06%
2004 224.705.000 2.26%
2005 200.306.000 -12.18%
2006 201.636.000 0.66%
2007 179.554.000 -12.3%
2008 149.036.000 -20.48%
2009 109.776.000 -35.76%
2010 124.389.000 11.75%
2011 113.379.000 -9.71%
2012 78.447.000 -44.53%
2013 69.064.000 -13.59%
2014 115.906.000 40.41%
2015 67.712.000 -71.17%
2016 41.778.000 -62.08%
2017 53.598.000 22.05%
2018 48.442.000 -10.64%
2019 69.051.000 29.85%
2020 45.681.000 -51.16%
2021 38.427.000 -18.88%
2022 15.979.000 -140.48%
2023 14.250.000 -12.13%
2023 13.021.000 -9.44%
2024 12.972.000 -0.38%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Interpace Biosciences, Inc. Liabilities
Year Liabilities Growth
1997 13.500.000
1998 22.300.000 39.46%
1999 42.200.000 47.16%
2000 132.115.000 68.06%
2001 151.736.000 12.93%
2002 67.728.000 -124.04%
2003 81.135.000 16.52%
2004 59.280.000 -36.87%
2005 64.696.000 8.37%
2006 52.439.000 -23.37%
2007 39.365.000 -33.21%
2008 41.929.000 6.12%
2009 34.886.000 -20.19%
2010 54.876.000 36.43%
2011 53.856.000 -1.89%
2012 42.817.000 -25.78%
2013 36.585.000 -17.03%
2014 95.784.000 61.8%
2015 54.674.000 -75.19%
2016 35.247.000 -55.12%
2017 13.629.000 -158.62%
2018 15.504.000 12.09%
2019 56.025.000 72.33%
2020 74.764.000 25.06%
2021 80.845.000 7.52%
2022 79.051.000 -2.27%
2023 30.394.000 -160.09%
2023 28.157.000 -7.94%
2024 25.462.000 -10.58%

Interpace Biosciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
9.52
Net Income per Share
0.64
Price to Earning Ratio
3.13x
Price To Sales Ratio
0.21x
POCF Ratio
2.44
PFCF Ratio
2.87
Price to Book Ratio
-0.7
EV to Sales
0.36
EV Over EBITDA
3
EV to Operating CashFlow
4.23
EV to FreeCashFlow
4.95
Earnings Yield
0.32
FreeCashFlow Yield
0.35
Market Cap
0,01 Bil.
Enterprise Value
0,02 Bil.
Graham Number
6.42
Graham NetNet
-4.15

Income Statement Metrics

Net Income per Share
0.64
Income Quality
1.2
ROE
-0.11
Return On Assets
0.22
Return On Capital Employed
-0.73
Net Income per EBT
0.93
EBT Per Ebit
0.68
Ebit per Revenue
0.11
Effective Tax Rate
0.01

Margins

Sales, General, & Administrative to Revenue
0.2
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.58
Operating Profit Margin
0.11
Pretax Profit Margin
0.07
Net Profit Margin
0.07

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.82
Free CashFlow per Share
0.7
Capex to Operating CashFlow
0.14
Capex to Revenue
0.01
Capex to Depreciation
0.82
Return on Invested Capital
-1.07
Return on Tangible Assets
0.22
Days Sales Outstanding
54.35
Days Payables Outstanding
37.13
Days of Inventory on Hand
25.96
Receivables Turnover
6.72
Payables Turnover
9.83
Inventory Turnover
14.06
Capex per Share
0.12

Balance Sheet

Cash per Share
0,46
Book Value per Share
-2,85
Tangible Book Value per Share
-2.85
Shareholders Equity per Share
-2.85
Interest Debt per Share
2.12
Debt to Equity
-0.67
Debt to Assets
0.65
Net Debt to EBITDA
1.26
Current Ratio
0.53
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-6103000
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
1192500
Debt to Market Cap
0.95

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Interpace Biosciences, Inc. Dividends
Year Dividends Growth

Interpace Biosciences, Inc. Profile

About Interpace Biosciences, Inc.

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

CEO
Dr. Thomas W. Burnell Ph.D.
Employee
108
Address
Morris Corporate Center 1
Parsippany, 07054

Interpace Biosciences, Inc. Executives & BODs

Interpace Biosciences, Inc. Executives & BODs
# Name Age
1 Dr. Thomas W. Burnell Ph.D.
President, Chief Executive Officer & Chairman
70
2 Mr. Patrick Kane
Vice President & Corporate Controller
70
3 Dr. Sydney D. Finkelstein M.D.
Chief Scientific Officer
70
4 Dr. Nicole Massoll M.D.
Chief Medical Officer
70
5 Mr. Christopher McCarthy
Chief Financial Officer
70
6 Mr. Jody Campbell
Chief Revenue Officer
70

Interpace Biosciences, Inc. Competitors